Moreover, gedatolisib and palbociclib also showed additive growth-inhibitory effects in HCC1806, an RB-positive, PIK3CA-amplified, triple negative breast cancer cell line that is relatively resistant to palbociclib [67] (Figure S12). The gene discussed is PIK3CA; the disease is triple-negative breast carcinoma.